Home › NDC Lookup › Ingredients › Levonorgestrel And Ethinyl Estradiol › 70700-0116-85
📦image loading
(from DailyMed)

ALTAVERA Levonorgestrel and Ethinyl Estradiol Kit — NDC 70700-116-85 (Billing 70700-0116-85)

by Xiromed, LLC. · 3 BLISTER PACK in 1 CARTON / 1 KIT in 1 BLISTER PACK

This is a package of ALTAVERA Levonorgestrel and Ethinyl Estradiol Kit from Xiromed, LLC., marketed since Sep 2022 and currently FDA-listed; retail pharmacies pay about $0.1135 per unit (NADAC). It is this product's only package size.

NDC 70700-0116-85
🏷️ FDA NDC (as labeled) 70700-116-85 billing pads the product segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 70700-116-85
Product NDC 70700-116
11-digit billing NDC 70700011685
NCPDP billing unit EA — each (per item)
RxCUI 238019, 748797, 748878, 1006065
UPC 0370700116852
Application # ANDA079102
SPL Set ID 4701e72b-6378-a771-fb88-1b703031a8bc
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2022-09-01
Dosage form KIT
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 25990002400310
GPI class Altavera
GCN Seq No 003314
GCN 11530
HICL code 001460
Ingredient (HICL) Levonorgestrel/Ethin.estradiol
HIC1 code G
Therapeutic class — broad (HIC1) Female Genital System
HIC2 code G8
Therapeutic class — intermediate (HIC2) Systemic Antifertility Agents
HIC3 code G8A
Therapeutic class — specific (HIC3) Contraceptives,Oral
AHFS code 68:12.00.00
AHFS class Contraceptives
FDB label name ALTAVERA-28 TABLET
FDB brand name Altavera
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 003314
  • GCN: 11530
  • GPI-14 (Medi-Span): 25990002400310
  • HICL (First Databank): 001460
  • AHFS class code: 68:12.00.00
  • RxCUI (RxNorm): 238019
Why two NDCs? The FDA registers this code as 70700-116-85 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 70700-0116-85. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Estrogen class.

Pharmacologic class Estrogen
Drug family (ATC) Progestogens and estrogens, sequential preparations, Natural and semisynthetic estrogens, plain, Estrogens
How it works Estrogen Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name ALTAVERA-28 TABLET Ingredient Levonorgestrel/Ethin.estradiol
📗 Our plain-language guide HelloPharmacist
  • It prevents pregnancy. It is a combined hormonal birth control with an estrogen and a progestin. It comes as daily tablets or as the weekly Twirla patch.
  • With tablets, you take one at the same time every day, no more than 24 hours apart. With the Twirla patch, you wear one patch for a week, three weeks in a row, then take a patch-fr...
  • Headache, nausea, acne, breast tenderness, mood changes, and irregular bleeding are the common ones. Bleeding changes often settle with time. Call your doctor if they persist.
  • Get help for chest pain, sudden shortness of breath, leg swelling or pain, vision loss, or severe new headaches. These can signal a blood clot or stroke. Also report yellowing of y...
📖 Read our full Ethinyl Estradiol / Levonorgestrel guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.114 $0.34 / 3 kit
Medicaid paysCMS SDUD · 12 mo $0.2865 $0.86 / 3 kit
Medicare drug plans payPart D · Q2 2026 $0.1851 $0.56 / 3 kit
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.182 $0.109
▼ Down 37% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
70700-0116-85 You're viewing this Main listing 3 BLISTER PACK in 1 CARTON / 1 KIT in 1 BLISTER PACK 2023-03-02 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Levonorgestrel And Ethinyl Estradiol 00378-6550-53 Mylan 3 pouches $0.113 AB Discontinued save 1%
Altaverathis 70700-0116-85 Xiromed, 1 kit $0.114 AB Availability likely —
Ayuna 65862-0848-88 Aurobindo 3 pouches $0.114 AB Availability likely —
Chateal EQ 50102-0230-23 Afaxys 3 pouches $0.114 AB Availability likely —
Marlissa 68462-0388-29 Glenmark 1 kit $0.114 AB Availability likely —
Kurvelo 68180-0844-73 Lupin 63 tablets $0.114 AB Availability likely —
Portia 00555-9020-58 Teva 6 pouches $0.114 — Availability likely —
Daysee 68180-0846-13 Lupin 2 pouches $0.125 AB Availability likely +10%
Levora 51862-0097-06 Mayne 1 kit $0.145 AB Discontinued +27%
Levonorgestrel And Ethinyl Estradiol 00378-7287-53 Mylan 3 pouches $0.151 AB1 Availability likely +33%
Lutera 51862-0028-06 Mayne 1 kit $0.152 AB1 Discontinued +34%
Lessina 00555-9014-67 Teva 3 pouches $0.154 — Availability likely +35%
Aubra EQ 50102-0220-23 Afaxys 3 pouches $0.154 AB1 Availability likely +35%
Levonorgestrel and Ethinyl Estradiol 68180-0854-73 Lupin 1 kit $0.154 AB1 Availability likely +35%
Aviane 00555-9045-58 Teva 6 pouches $0.154 — Availability likely +35%
Vienva 70700-0118-85 Xiromed, 1 kit $0.154 AB1 Availability likely +35%
Falmina 16714-0359-01 Northstar 1 packet $0.154 AB1 Availability likely +35%
Sronyx 51862-0545-06 Mayne 1 kit $0.174 AB2 Discontinued +53%
Introvale 70700-0117-87 Xiromed, 1 kit $0.184 AB FDA listed +62%
Afirmelle 65862-0849-88 Aurobindo 3 pouches $0.225 AB1 FDA listed +98%
Iclevia 65862-0865-83 Aurobindo 3 pouches $0.227 AB FDA listed +100%
Setlakin 16714-0366-03 Northstar 3 pouches $0.227 AB Availability likely +100%
Levonorgestrel and Ethinyl Estradiol 68180-0843-13 Lupin 1 kit $0.227 AB Availability likely +100%
levonorgestrel and ethinyl estradiol 68462-0672-95 Glenmark 3 pouches $0.227 AB Availability likely +100%
Levonorgestrel and Ethinyl Estradiol and Ethinyl Estradiol 68180-0848-13 Lupin 2 pouches $0.239 AB Availability likely +111%
Levonest 16714-0340-01 Northstar 1 packet $0.324 AB Availability likely +185%
Levonorgestrel and Ethinyl Estradiol 68180-0857-73 Lupin 1 kit $0.324 AB Availability likely +185%
Tyblume 00642-7471-01 Exeltis 1 kit $0.828 — Availability likely +629%
levonorgestrel and ethinyl estradiol 42192-0623-03 Acella 1 kit $3.445 AB3 Availability likely +2935%
Levonest 50090-2505-00 A-S 1 kit — AB FDA listed —
Kurvelo 50090-6374-00 A-S 21 tablets — AB FDA listed —
Altavera 63629-2343-01 Bryant 1 kit — AB FDA listed —
Lutera 55741-0005-06 Dr. 1 kit — AB1 FDA listed —
Balcoltra 75854-0602-02 Avion 1 kit — AB3 FDA listed —
Vienva Tm 50090-5580-00 A-S 1 kit — AB1 FDA listed —
Levonorgestrel and Ethinyl Estradiol 79929-0003-07 Naari 1 kit — AB FDA listed —
Levonorgestrel and Ethinyl Estradiol 60505-4898-08 Apotex 1 kit — AB1 FDA listed —
Levonorgestrel and Ethinyl Estradiol 60505-4899-08 Apotex 1 kit — AB FDA listed —
Vienva TM 63629-2344-01 Bryant 1 kit — AB1 FDA listed —
Levonorgestrel and Ethinyl Estradiol 79929-0004-07 Naari 1 kit — AB1 FDA listed —
Aviane 63187-0889-28 Proficient 1 pouch — — FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2022
On the market since
Sep 2022
📍
2026
Currently FDA-listed
4 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerXiromed, LLC.
Application holderXIROMED PHARMA ESPANA SL
FDA applicationANDA079102 (ANDA)
Labeler code70700
First marketedSep 2022
Product typeHuman Prescription Drug
Portfolio13 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🚨 Boxed Warning 🎯 Indications and Usage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description 📄 Patient Package Insert 📖 Instructions for Use 📄 Package Label / Principal Display Panel
🚨 Boxed Warning 66 words ▾

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including Altavera, are contraindicated in women who are over 35 years of age and smoke [see CONTRAINDICATIONS and WARNINGS (1)].

🎯 Indications and Usage 16 words ▾

INDICATIONS AND USAGE Altavera is indicated for use by females of reproductive potential to prevent pregnancy.

🧬 Clinical Pharmacology 11 words ▾

CLINICAL PHARMACOLOGY Combination oral contraceptives prevent pregnancy primarily by suppressing ovulation.

📦 How Supplied / Storage and Handling 117 words ▾

HOW SUPPLIED/STORAGE AND HANDLING Altavera tablets (levonorgestrel and ethinyl estradiol, 0.15 mg/30 mcg) are available in a carton containing three blister cards, each containing 28 tablets: 21 Active Tablets: Peach, round, unscored, debossed with SZ on one side and J4 on the other side. 7 Inert Tablets: White, round, unscored, debossed with SZ on one side and J1 on the other side. 1 individual blister NDC 70700-116-84 Carton with 3 blisters NDC 70700-116-85 Store at 20º to 25°C (68° to 77º F) [See USP Controlled Room Temperature].

ALTAVERA is a registered trademark of Xiromed Pharma España, S.L. Manufactured by Laboratorios Leon Farma S.A., Spain for Xiromed, LLC., Florham Park, NJ 07932 Product of Spain PI-116-06 Rev. 02/2023

📋 Description 128 words ▾

DESCRIPTION Altavera (levonorgestrel and ethinyl estradiol tablets) is a combination oral contraceptive (COC) consisting of 21 peach active tablets, each containing 0.15 mg of levonorgestrel, a synthetic progestin and 30 mcg of ethinyl estradiol, an estrogen, and 7 white inert tablets (without hormones). The structural formulas for the active components are: Levonorgestrel C 21 H 28 O 2 MW: 312.4 Ethinyl Estradiol C 20 H 24 O 2 MW: 296.4 Ethinyl Estradiol is 19-nor-17α-pregna-1,3,5(10)-trien-20-yne-3, 17-diol. Each peach active tablet contains the following inactive ingredients: lactose anhydrous, iron oxide black, iron oxide red, iron oxide yellow, magnesium stearate, polyethylene glycol, polyvinyl alcohol-part hydrolyzed, povidone, talc, titanium dioxide.

Each white inert tablet contains the following inactive ingredients: lactose anhydrous, magnesium stearate, polyethylene glycol, polyvinyl alcohol-part hydrolyzed, povidone, talc, titanium dioxide.

📄 Patient Package Insert ~3 min read ▾

Patient Information ALTAVERA ® [ all-tuh-VAIR-u h] (levonorgestrel 0.15 mg and ethinyl estradiol 30 mcg tablets) What is the most important information I should know about Altavera? Do not use Altavera if you smoke cigarettes and are over 35 years old. S moking increases your risk of serious cardiovascular side effects from hormonal birth control pills, including death from heart attack, blood clots or stroke.

This risk increases with age and the number of cigarettes you smoke. What is Altavera? Altavera is a birth control pill (oral contraceptive) used by women to prevent pregnancy.

How does Altavera work for contraception? Your chance of getting pregnant depends on how well you follow the directions for taking your birth control pills. The better you follow the directions, the less chance you have of getting pregnant.

Based on the results of clinical studies, about 1 to 5 out of 100 women may get pregnant during the first year they use Altavera. The following chart shows the chance of getting pregnant for women who use different methods of birth control. Each box on the chart contains a list of birth control methods that are similar in effectiveness.

The most effective methods are at the top of the chart. The box on the bottom of the chart shows the chance of getting pregnant for women who do not use birth control and are trying to get pregnant. Who should not take Altavera?

Do not take Altavera if you: • smoke and are over 35 years of age • had blood clots in your arms, legs, lungs, or eyes • had a problem with your blood that makes it clot more than normal • have certain heart valve problems or irregular heart beat • had a stroke • had a heart attack • have high blood pressure that cannot be controlled by medicine • have diabetes with kidney, eye, nerve, or blood vessel damage • have certain kinds of severe migraine headaches with aura, numbness, weakness or changes in vision, or any migraine headaches if you are over 35 years of age • had breast cancer or any cancer that is sensitive to female hormones • have liver problems, including liver tumors • have any unexplained vaginal bleeding • are pregnant • take any Hepatitis C drug combination containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir.

This may increase levels of the liver enzyme “alanine aminotransferase” (ALT) in the blood. If any of these conditions happen while you are taking Altavera, stop taking Altavera right away and talk to your healthcare provider. Use non-hormonal contraception when you stop taking Altavera.

What should I tell my healthcare provider before taking Altavera? Tell your healthcare provider if you: • are pregnant or think you may be pregnant • are depressed now or have been depressed in the past • had yellowing of your skin or eyes (jaundice) caused by pregnancy (cholestasis of pregnancy) • are breastfeeding or plan to breastfeed. Altavera may decrease the amount of breast milk you make.

A small amount of the hormones in Altavera may pass into your breast milk. Talk to your healthcare provider about the best birth control method for you while breastfeeding. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

Altavera may affect the way other medicines work, and other medicines may affect how well Altavera works. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I take Altavera? Read the Instructions for Use at the end of this Patient Information. What are the possible serious side effects of Altavera? • Like pregnancy, Altavera may cause serious side effects, including blood clots in your lungs, heart attack, or a stroke that may lead to death.

Some other examples of serious blood clots include blood clots in the legs or eyes. Serious blood clots can happen especially if you smoke, are obese, or are older than 35 years of age. Serious bloo… [Excerpted — this section continues on DailyMed.]

📖 Instructions for Use ~3 min read ▾

Instructions For Use ALTAVERA [all-tuh-VAIR-uh] (levonorgestrel 0.15 mg and ethinyl estradiol tablets 30 mcg) Important Information about taking Altavera • Take 1 pill every day at the same time. Take the pills in the order directed on your pill pack. • Do not skip your pills, even if you do not have sex often. If you miss pills (including starting the pack late) you could get pregnant.

The more pills you miss, the more likely you are to get pregnant. • If you have trouble remembering to take Altavera, talk to your healthcare provider. • When you first start taking Altavera, spotting or light bleeding in between your periods may occur. Contact your healthcare provider if this does not go away after a few months. • You may feel sick to your stomach (nauseous), especially during the first few months of taking Altavera. If you feel sick to your stomach, do not stop taking the pill.

The problem will usually go away. If your nausea does not go away, call your healthcare provider. • Missing pills can also cause spotting or light bleeding, even when you take the missed pills later. On the days you take 2 pills to make up for missed pills (see What should I do if I miss any Altavera pills? below), you could also feel a little sick to your stomach. • It is not uncommon to miss a period.

However, if you miss a period and have not taken Altavera according to directions, or feel like you may be pregnant, call your healthcare provider. If you have a positive pregnancy test, you should stop taking Altavera. • If you have vomiting or diarrhea within 3-4 hours of taking a light-orange pill, take another light-orange pill as soon as possible. Continue taking all your remaining pills in order.

Start the first pill of your next pill pack the day after finishing your current pill pack. This will be 1 day earlier than originally scheduled. Continue on your new schedule. • If you have vomiting or diarrhea for more than 1 day, your birth control pills may not work as well.

Use an additional birth control method, like condoms or spermicide, until you check with your healthcare provider. • Stop taking Altavera at least 4 weeks before you have major surgery and do not restart after the surgery without asking your healthcare provider. Be sure to use other forms of contraception (like condoms or spermicide) during this time period. Before you start taking Altavera: • Decide what time of day you want to take your pill.

It is important to take it at the same time every day and in the order as directed on your pill pack. • Look at your pill pack. Your pill pack consists of 1 card that holds 28 individually sealed pills. The 28 pills consist of 21 light-orange pills (3 rows of 7 pills) and 7 pink pills (1 row of 7 pills).

See Figure A . Figure A • Also find: o Where on the card to start taking pills (upper left corner) and o In what order to take the pills (follow the weeks) • Be sure you have ready at all times another kind of birth control (such as condoms or spermicide), to use as a back-up in case you miss pills. When should I start taking Altavera?

If you start taking Altavera and you have not used a hormonal birth control method before: • There are 2 ways to start taking your birth control pills. You can either start on a Sunday (Sunday Start) or on the first day (Day 1) of your natural menstrual period (Day 1 Start). Your healthcare provider should tell you when to start taking your birth control pill. • If you use the Sunday Start, use non-hormonal back-up contraception such as condoms or spermicide for the first 7 days that you take Altavera.

You do not need back-up contraception if you use the Day 1 Start. If you start taking Altavera and you are switching from another birth control pill: • Start your new Altavera pack on the same day that you would start the next pack of your previous birth control method. • Do not continue taking the pills from your previous birth control pill pack. If you start taking Altavera and previously used a vaginal ring:… [Excerpted — this section continues on DailyMed.]

📄 Package Label / Principal Display Panel 18 words ▾

Principal Display Panel NDC 70700-116-85 ALTAVERA ® (Levonorgestrel and Ethinyl Estradiol Tablets, USP) 0.15 mg/0.03 mg Rx Only

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
32.2K
Units reimbursed last 4 qtrs
2M
Gross reimbursed last 4 qtrs
$583.6K
Avg / prescription
$18.11
Avg / unit
$0.2865
Latest quarter Q1 2026
7.4KRx
Medicaid pays / ea
$0.2865
gross reimbursed
vs
NADAC / ea
$0.1135
acquisition cost
=
Spread
+$0.1730
+152% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
37% FFS 63% MCO
Fee-for-service · 11,775 Rx Managed care · 20,442 Rx
State Medicaid map
Alaska: 4,844 units · 661 per 100k residents AK Maine: 10,164 units · 729 per 100k residents ME Washington: 113,792 units · 1,457 per 100k residents WA Idaho: 7,196 units · 366 per 100k residents ID Montana: 9,744 units · 861 per 100k residents MT North Dakota: 7,140 units · 912 per 100k residents ND Minnesota: 36,176 units · 631 per 100k residents MN Wisconsin: 35,787 units · 606 per 100k residents WI Michigan: 52,164 units · 520 per 100k residents MI New York: 274,532 units · 1,403 per 100k residents NY Vermont: 19,460 units · 3,008 per 100k residents VT New Hampshire: 8,848 units · 631 per 100k residents NH Oregon: 67,396 units · 1,592 per 100k residents OR Nevada: 3,668 units · 115 per 100k residents NV Wyoming: no data reported WY South Dakota: 5,152 units · 561 per 100k residents SD Iowa: 13,664 units · 426 per 100k residents IA Illinois: 48,636 units · 388 per 100k residents IL Indiana: 61,068 units · 890 per 100k residents IN Ohio: 95,116 units · 807 per 100k residents OH Pennsylvania: 215,096 units · 1,660 per 100k residents PA New Jersey: 49,672 units · 535 per 100k residents NJ Massachusetts: 150,164 units · 2,145 per 100k residents MA California: 156,369 units · 401 per 100k residents CA Utah: 1,540 units · 45.1 per 100k residents UT Colorado: 25,788 units · 439 per 100k residents CO Nebraska: 6,076 units · 307 per 100k residents NE Missouri: 21,532 units · 348 per 100k residents MO Kentucky: 18,928 units · 418 per 100k residents KY West Virginia: 16,520 units · 933 per 100k residents WV Virginia: 56,644 units · 650 per 100k residents VA Maryland: 94,696 units · 1,532 per 100k residents MD Connecticut: 62,748 units · 1,735 per 100k residents CT Rhode Island: 22,764 units · 2,079 per 100k residents RI Arizona: 6,748 units · 90.8 per 100k residents AZ New Mexico: 12,236 units · 579 per 100k residents NM Kansas: 4,711 units · 160 per 100k residents KS Arkansas: 4,564 units · 149 per 100k residents AR Tennessee: 8,904 units · 125 per 100k residents TN North Carolina: 61,712 units · 570 per 100k residents NC South Carolina: 33,488 units · 623 per 100k residents SC Delaware: 4,396 units · 426 per 100k residents DE Oklahoma: 5,712 units · 141 per 100k residents OK Louisiana: 6,748 units · 148 per 100k residents LA Mississippi: 1,512 units · 51.4 per 100k residents MS Alabama: 13,524 units · 265 per 100k residents AL Georgia: 18,004 units · 163 per 100k residents GA D.C.: 8,098 units · 1,193 per 100k residents DC Hawaii: 840 units · 58.5 per 100k residents HI Texas: 52,500 units · 172 per 100k residents TX Florida: 20,331 units · 89.9 per 100k residents FL
Units reimbursed · per 100k residents
45.13,008
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Vermont 3,008 /100k
2 Massachusetts 2,145 /100k
3 Rhode Island 2,079 /100k
4 Connecticut 1,735 /100k
5 Pennsylvania 1,660 /100k
6 Oregon 1,592 /100k
7 Maryland 1,532 /100k
8 Washington 1,457 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Altavera — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Altavera. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$22.1K
Claims incl. refills
936
Beneficiaries
600
Spend / beneficiary
$36.84
Spend / claim
$23.61
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Finished prescription product Kit / multi-component package

Kit / multi-component package

This NDC identifies a kit — a package containing more than one component. Structured data (pricing, ingredients, equivalents) is often reported per component rather than for the kit NDC itself, which can make this page look thinner than the components' own pages.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Xiromed, LLC.. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Xiromed, LLC. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 70700-0115-85 · Xiromed, 70700-0117-87 · Xiromed, →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.